Articles

May 20, 2012

2012: A Pivotal Year for Alzheimer’s Disease Drug Development

April 10, 2012 By MD Becker Partners Leave a Comment

An overview of product candidates in clinical trials and the more than 30 life science companies developing novel therapies for Alzheimer’s disease

Filed Under: Articles Tagged With: AD, Alzheimer's Association International Conference, Alzheimer's disease, Amyvid, bapineuzumab, Elan, Eli Lilly & Co, ELN, Grupo Zeltia, International Conference on Alzheimer’s’ Disease, Janssen, JNJ, Johnson & Johnson, LLY, National Alzheimer’s Project Act, Noscira, PFE, Pfizer, President Obama, solanezumab, tideglusib

Thinking of Spring – Tulips and Cancer Stem Cell Mania

March 4, 2012 By MD Becker Partners Leave a Comment

With spring around the corner, it seemed an appropriate time to examine Wall Street’s latest tulip obsession, which relates to the potential of targeting cancer stem cells…

Filed Under: Articles Tagged With: acute myeloid leukemia, AML, BBI608, Boston Biomedical, cancer, cancer stem cells, CSC, CSCs, Dainippon Sumitomo Pharma Co., Eclipse Therapeutics, ENMD, EntreMed, EphA3, ET-101, Formula Pharmaceuticals, GERN, Geron Corporation, GRN163L, ICT-107, Imetelstat, ImmunoCellular Therapeutics Ltd., IMUC.OB, KaloBios Pharmaceuticals, KB004, OMP-21M18, OncoMed Pharmaceuticals, SL-401, Stemica LLC, Stemline Therapeutics, telomerase inhibitor, Verastem, VS-4718, VS-507, VS-5095, VSTM, WT1

Rethinking Immunotherapy for Brain Tumors

February 22, 2012 By MD Becker Partners Leave a Comment

Eight companies with immunotherapy approaches for brain tumors

Filed Under: Articles Tagged With: AGEN, Agenus, astrocytoma, biotechnology, brain cancer, Celldex Therapeutics, CLDX, Dendreon, dendritic cell, DNDN, GBM, GlaxoSmithKline, Glioblastoma multiforme, glioma, GSK, heat-shock protein, HSPPC-96, Immatics Biotechnologies, immunotherapy, IMUC, Innocell Corp, JNJ, Johnson & Johnson, mmunoCellular Therapeutics, Northwest Biotherapeutics, NWBO, Oncovir, prophage, TVAX Biomedical

2011 Review and Outlook for Biotechnology in 2012

January 25, 2012 By MD Becker Partners Leave a Comment

Our favorable outlook for the biotechnology industry remains intact for 2012 and is based on several key drivers

Filed Under: Articles Tagged With: 2011, 2012, Access to Capital, Akorn, AKRX, BDSI, BioDelivery Sciences, biotechnology, BMY, Bristol-Myers Squibb, Canaan Partners, consolidation, defensive sector, Dendreon, DNDN, Economic Driver, Endo Pharmaceuticals, ENDP, FDA, Flagship Ventures, HGSI, Human Genome Sciences, Inc., Inhibitex, INHX, ISTA, ISTA Pharmaceuticals, M&A, MDVN, Medivation, NASDAQ, New Drug Approvals, outlook, PhRMA, Pipeline, Review, RHHBY, roche, Valeant Pharmaceuticals, Vivo Ventures, VRX, Xenon Pharmaceuticals

2012 Preview: Cancer Immunotherapy Catalysts

December 14, 2011 By MD Becker Partners 1 Comment

MD Becker Partners' Life Science Digest: 2012 graphic

2012 represents a period with robust news flow for emerging immuno-oncology companies

Filed Under: Articles Tagged With: AE37, AGEN, Agenus, Allovectin, Amgen, AMGN, Antigen Express, BAVA, Bavarian Nordic, BMY, Bristol-Myers Squibb, cancer vaccine, castrate-resistant prostate cancer, CELG, Celgene, Celldex Therapeutics, CLDX, cv-301, Dendreon, DNDN, Generex, GlaxoSmithKline, GlobeImmune, GNBT, gp100, GSK, HyperAcute, Idera Pharmaceuticals, IDRA, immunotherapy, IMO-2055, ipilimumab, Jennerex, JX-594, MAGE-A3, melanoma, NewLink Genetics, NLNK, NSCLC, Oncothyreon, OncoVex, ONTY, pancreatic cancer, panvac, PROSTVAC, Provenge, QS-21, sipuleucel-T, Stimuvax, TG4010, transgene, Vical, VICL, Yervoy

2012: A Pivotal Year for Alzheimer’s Disease Drug Development

Thinking of Spring – Tulips and Cancer Stem Cell Mania

Rethinking Immunotherapy for Brain Tumors

2011 Review and Outlook for Biotechnology in 2012

2012 Preview: Cancer Immunotherapy Catalysts

Download the Life Science Digest App

Featured Video

About Life Science Digest

Like Us on Facebook

2012: A Pivotal Year for Alzheimer’s Disease Drug Development

Thinking of Spring – Tulips and Cancer Stem Cell Mania

Rethinking Immunotherapy for Brain Tumors

2011 Review and Outlook for Biotechnology in 2012

2012 Preview: Cancer Immunotherapy Catalysts

Download the Life Science Digest App

Follow MD Becker Partners

Featured Video

About Life Science Digest

Article Tag Cloud

Like Us on Facebook